Trials / Conditions / Recurrent Mycosis Fungoides and Sezary Syndrome

Recurrent Mycosis Fungoides and Sezary Syndrome

8 registered clinical trials studyying Recurrent Mycosis Fungoides and Sezary Syndrome.

Status	Trial	Sponsor	Phase
Terminated	Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogam NCT04541017	National Cancer Institute (NCI)	Phase 1 / Phase 2
Completed	Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatme NCT03063632	National Cancer Institute (NCI)	Phase 2
Withdrawn	Reduced Intensity Conditioning Before Partially Matched Donor Stem Cell Transplant in Treating Patients With A NCT02548468	Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University	Phase 1
Completed	Pembrolizumab in Treating Patients With Relapsed or Refractory Stage IB-IVB Mycosis Fungoides or Sezary Syndro NCT02243579	National Cancer Institute (NCI)	Phase 2
Completed	Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-C NCT01567709	National Cancer Institute (NCI)	Phase 1
Completed	Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma NCT01326702	National Cancer Institute (NCI)	Phase 1 / Phase 2
Completed	Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers NCT01254578	National Cancer Institute (NCI)	Phase 1
Completed	Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surg NCT00608361	National Cancer Institute (NCI)	Phase 1